In addition, this led to the discovery of a pertinent and druggable therapeutic target to trigger an immune response against EBV-related cancers: the interaction between NCL and the G4s of GAr-encoding sequence of the EBNA1 mRNA. Here, NUCLEOLIN is linked to cancer.